Drugging the undruggable RAS: Mission Possible?
Open accessThe DOI matches its Crossref record; 231 of the 231 references it cites were found in a registry or an index.
Abstract
Despite more than three decades of intensive effort, no effective pharmacological inhibitors of the RAS oncoproteins have reached the clinic, prompting the widely held perception that RAS proteins are 'undruggable'. However, recent data from the laboratory and the clinic have renewed our hope for the development of RAS-inhibitory molecules. In this Review, we summarize the progress and the promise of five key approaches. Firstly, we focus on the prospects of using direct inhibitors of RAS. Secondly, we address the issue of whether blocking RAS membrane association is a viable approach. Thirdly, we assess the status of targeting RAS downstream effector signalling, which is arguably the most favourable current approach. Fourthly, we address whether the search for synthetic lethal interactors of mutant RAS still holds promise. Finally, RAS-mediated changes in cell metabolism have recently been described and we discuss whether these changes could be exploited for new therapeutic directions. We conclude with perspectives on how additional complexities, which are not yet fully understood, may affect each of these approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“KRAS has historically been considered ‘undruggable’ owing to a lack of pharmacologically targetable pockets within the mutant isoforms.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genetic analysis has shown that 98% of RAS mutations that cause cancer are concentrated in three residues: G12, G13, and Q61.”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of highly selective and potent inhibitors have been developed against kinases in the Ras signaling network particularly those in the MAPK and PI3K/mTOR pathways (9, 12).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For more than 40 years, KRAS mutation has been considered “undruggable” [16, 17].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For many proteins known to be involved in driving diseases, such as KRAS in many cancers, conventional drug development strategies often aimed at developing inhibitors have failed [118, 119].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [119]
Experimental — accuracy not yet measured
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890
Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation
Lunt, S. Y., & Vander Heiden, M. G. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154237 · Cited by 3,057
Research works printed but not linked: 1
- Kumar, M. S. et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 149, 642–655 (2012). · DOI · Paper page
Cited by
Items 701–800 of 1,007
Decroocq, J., Birsen, R., Montersino, C., Chaskar, P., Mano, J., Poulain, L., Friedrich, C., Alary, A., Guermouche, H., Sahal, A., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01541-0 · Cited by 30
“These are small protein GTPases, regulated by a switch between active GTP-linked and inactive GDP-bound states that is governed by a complex network of guanine exchange factors (GEFs, favoring RAS-GTP) and GTPase activating factors (GAPs, favoring RAS-GDP) [2].”
BackgroundInfluentialComputational allosteric ligand binding site identification on Ras proteins
McCarthy, M. J., Prakash, P., & Gorfe, A. A. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv100 · Cited by 31
“Therefore, Ras proteins remain one of the most crucial anticancer drug targets [14].”
BackgroundPodbevšek, P., & Plavec, J. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1359 · Cited by 28
Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer
Kitai, H., & Ebi, H. (2016) · Small GTPases · doi:10.1080/21541248.2016.1210369 · Cited by 30
“Mutations in KRAS impair the intrinsic GTPase activity of KRAS, causing it to accumulate in a constitutively active GTP-bound state.(1,2) In contrast to the successful development of ATPcompetitive small molecule inhibitors blocking mutant”
BackgroundRas sumoylation in cell signaling and transformation
Dai, W., Xie, S., Chen, C., & Choi, B. H. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.033 · Cited by 27
Ye, H., Liu, Y., Wu, K., Luo, H., & Cui, L. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00584-z · Cited by 27
Huang, Y., Zhang, W., Li, Q., Wang, Z., & Yang, X. (2023) · Scientific Reports · doi:10.1038/s41598-023-30865-9 · Cited by 29
Discovery and Characterization of RP03707: A Highly Potent and Selective KRAS G12D PROTAC
Ji, X. L., Li, H., Wu, G., Zhang, Q., He, X., Wu, Y., Zong, B., Xu, X., Liang, C., Wang, B., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00428 · Cited by 32
Aurora kinase A interacts with H-Ras and potentiates Ras-MAPK signaling
Umstead, M., Xiong, J., Qi, Q., Du, Y., & Fu, H. (2017) · Oncotarget · doi:10.18632/oncotarget.15049 · Cited by 29
“Attempts to directly target Ras proteins for cancer treatment have been largely unsuccessful in the clinic [59, 60].”
BackgroundEnhancing anticancer activity of checkpoint immunotherapy by targeting RAS
Ward, A., Keeton, A. B., Chen, X., Mattox, T. E., Coley, A. B., Maxuitenko, Y. Y., Buchsbaum, D. J., Randall, T. D., Zhou, G., & Piazza, G. A. (2020) · MedComm · doi:10.1002/mco2.10 · Cited by 29
“RAS-driven cancers are generally the most lethal and unresponsive to chemotherapy and/or radiation and are therefore excluded from most therapies.11 In addition, individuals diagnosed with RAS mutant cancers have a lower life expectancy than those whose cancers are associated with other oncogenic driver mutations.12 A…”
BackgroundInfluentialHuang, Z., Liu, M., Li, D., Tan, Y., Zhang, R., Xia, Z., Wang, P., Jiao, B., Liu, P., & Ren, R. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011060 · Cited by 30
“KRAS4A and KRAS4B result from an alternative splicing at the C terminus of the KRAS gene (2).”
BackgroundA CRISPR-Cas9 repressor for epigenetic silencing of KRAS
Liu, J., Sun, M., Cho, K. B., Gao, X., & Guo, B. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105304 · Cited by 30
Erlanson, D. A., & Webster, K. R. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.02.010 · Cited by 30
Understand KRAS and the Quest for Anti-Cancer Drugs
Han, C. W., Jeong, M. S., & Jang, S. B. (2021) · Cells · doi:10.3390/cells10040842 · Cited by 29
“Recent studies have targeted KRAS downstream effector pathways [67].”
BackgroundEscaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
Adachi, Y., Kimura, R., Hirade, K., & Ebi, H. (2021) · Cancers · doi:10.3390/cancers13205081 · Cited by 30
“However, due to the picomolar affinity of GTP for KRAS, and the millimolar concentrations of cellular GTPs, the development of direct GTP inhibitors has been challenging [5,6].”
BackgroundZhou, Y., & Hancock, J. F. (2023) · FEBS Letters · doi:10.1002/1873-3468.14569 · Cited by 29
Manolakos, P., & Ward, L. D. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13061010 · Cited by 27
“They are found in 30–35% of NSCLC adenocarcinomas, with the KRAS G12C variant being the most common [6].”
BackgroundSignalling Pathways Controlling Cellular Actin Organization
Steffen, A., Stradal, T. E. B., & Rottner, K. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_35 · Cited by 31
“Despite being established as oncogenic proteins since decades – mutated Ras genes were the first genes being discovered in human cancers – Ras is still unsusceptible to pharmacological inhibition in clinical terms (Cox et al. 2014).”
BackgroundStructure-based development of PDEδ inhibitors
Martín-Gago, P., Fansa, E. K., Wittinghofer, A., & Waldmann, H. (2017) · Biological Chemistry · doi:10.1515/hsz-2016-0272 · Cited by 26
“Post-translational modifications of KRas, its regulators and effectors, structural features and oncogenic mutations have been extensively studied for more than a decade (Vigil et al., 2010; Cox et al., 2014).”
LvRas and LvRap are both important for WSSV replication in Litopenaeus vannamei
Tseng, Y.-T., Kumar, R., & Wang, H. (2019) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2019.02.035 · Cited by 28
Prognostic Role of KRAS mRNA Expression in Breast Cancer
Hwang, K., Kim, B. H., Oh, S., Park, S. Y., Jung, J., Kim, J.-J., Choi, I. S., Jeon, S. Y., & Kim, W. (2019) · Journal of Breast Cancer · doi:10.4048/jbc.2019.22.e55 · Cited by 27
“A previous study has shown that frequencies of KRAS mutations as: G12 (83%), G13 (14%), Q61 (2%), and others (1%) [6,30].”
BackgroundInfluentialKhrenova, M. G., Kulakova, A. M., & Nemukhin, A. V. (2020) · Organic & Biomolecular Chemistry · doi:10.1039/d0ob00071j · Cited by 28
Scratching the surface: native mass spectrometry of peripheral membrane protein complexes
Sahin, C., Reid, D. J., Marty, M. T., & Landreh, M. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190787 · Cited by 29
Yamada‐Hunter, S. A., McIntosh, B. J., Shi, Y., Sperberg, R. A. P., Funatogawa, C., Labanieh, L., Soon, E., Wastyk, H. C., Mehta, N., Carter, C., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01928-2 · Cited by 28
Head perturbations during walking while viewing a head-fixed target.
Das, V. E., Zivotofsky, A. Z., DiScenna, A. O., & Leigh, R. J. (1995) · PubMed · Cited by 30
Lipid Profiles of RAS Nanoclusters Regulate RAS Function
Zhou, Y., & Hancock, J. F. (2021) · Biomolecules · doi:10.3390/biom11101439 · Cited by 26
The TGF-β superfamily as potential therapeutic targets in pancreatic cancer
Tindall, R. R., Bailey, J. M., Cao, Y., & Ko, T. C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1362247 · Cited by 27
“KRAS is frequently mutated in human carcinomas and approximately 85% of PDAC cases (77).”
BackgroundBioactive atropisomers: Unraveling design strategies and synthetic routes for drug discovery
Liu, S., Zhao, Q., Liu, X., Gamble, A. B., Huang, W., Yang, Q., & Han, B. (2024) · Medicinal Research Reviews · doi:10.1002/med.22037 · Cited by 30
Driver Mutations in Pancreatic Cancer and Opportunities for Targeted Therapy
Olaoba, O. T., Adelusi, T. I., Yang, M. J., Maidens, T., Kimchi, E. T., Staveley-O’Carroll, K. F., & Li, G. (2024) · Cancers · doi:10.3390/cancers16101808 · Cited by 29
“It is the most mutated gene in all of the Ras family and therefore drives oncogenesis in most cancer cells [24,25]. is the most mutated gene in all of the Ras family and therefore drives oncogenesis in most cancer cells [24,25].”
BackgroundEvaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment
Long, S.-A., Amparo, A. M., Goodhart, G., Ahmad, S. A., & Waters, A. M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1402128 · Cited by 31
Lokhandwala, J., Smalley, T. B., & Tran, T. H. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1394702 · Cited by 29
“The Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most frequently mutated oncogene in cancers, and mutations in the RAS family affect approximately 30% of cancer diagnoses (1, 2).”
BackgroundGenome-wide DNA methylation analysis of KRAS mutant cell lines
Tew, B. Y., Durand, J. K., Bryant, K. L., Hayes, T. K., Peng, S., Tran, N. L., Gooden, G. C., Buckley, D. N., Der, C. J., Baldwin, A. S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-66797-x · Cited by 29
Self-citationA Leucine-Rich Repeat Protein Provides a SHOC2 the RAS Circuit: a Structure-Function Perspective
Kwon, J. J., & Hahn, W. C. (2021) · Molecular and Cellular Biology · doi:10.1128/mcb.00627-20 · Cited by 28
“RAS family proteins are known to be one of the most frequently mutated oncogenes, where ;30% of all cancers possess constitutively active mutations in KRAS, HRAS, or NRAS (75, 76).”
BackgroundHafezi, S., Saber-Ayad, M. M., & Abdel‐Rahman, W. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910219 · Cited by 28
Kumar, S. U., & Doss, C. G. P. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104946 · Cited by 26
Gong, R., Chen, M., Huang, C., Wong, H. L. X., Kwan, H. Y., & Bian, Z. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00834-2 · Cited by 30
Capelletto, E., Bironzo, P., Denis, L. J., Koustenis, A. G., Bungaro, M., & Novello, S. (2022) · Future Oncology · doi:10.2217/fon-2021-1582 · Cited by 28
SNAT7 regulates mTORC1 via macropinocytosis
Meng, D., Yang, Q., Jeong, M.-H., Curukovic, A., Tiwary, S., Melick, C. H., Lama-Sherpa, T. D., Wang, H., Huerta-Rosario, M., Urquhart, G., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2123261119 · Cited by 26
Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers
Cekani, E., Epistolio, S., Dazio, G., Cefalì, M., Wannesson, L., Frattini, M., & Froesch, P. (2022) · Cancers · doi:10.3390/cancers14174103 · Cited by 30
Natural Compounds Targeting the Autophagy Pathway in the Treatment of Colorectal Cancer
Du, Y.-X., Mamun, A. A., Lü, A., & Zhang, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087310 · Cited by 26
Entrialgo‐Cadierno, R., Cueto‐Ureña, C., Welch, C., Feliu, I., Macaya, I., Vera, L., Morales, X., Michelina, S. V., Scaparone, P., López, I., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01788-w · Cited by 28
“In lung and pancreatic ductal adenocarcinoma (LUAD and PDAC), KRAS mutation frequency reaches ~ 25 and 90% of cases respectively [1, 2].”
CRISPR prime editing for unconstrained correction of oncogenic KRAS variants
Jang, G., Kweon, J., & Kim, Y. (2023) · Communications Biology · doi:10.1038/s42003-023-05052-1 · Cited by 33
Small-molecule drugs of colorectal cancer: Current status and future directions
Yang, Y., Liu, P., Zhou, M., Yin, L., Wang, M., Liu, T., Jiang, X., & Gao, H. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166880 · Cited by 29
Ras suppression potentiates rear actomyosin contractility-driven cell polarization and migration
Lin, Y., Pal, D. S., Banerjee, P., Banerjee, T., Qin, G., Deng, Y., Borleis, J. A., Iglesias, P. A., & Devreotes, P. N. (2024) · Nature Cell Biology · doi:10.1038/s41556-024-01453-4 · Cited by 26
“8b and Supplementary Video 30).”
Reversible Effects of Peptide Concentration and Lipid Composition on H-Ras Lipid Anchor Clustering
Lin, X., Li, Z., & Gorfe, A. A. (2015) · Biophysical Journal · doi:10.1016/j.bpj.2015.11.009 · Cited by 26
Plessl, T., Bürer, C., Lutz, S., Yue, W. W., Baumgartner, M. R., & Froese, D. S. (2017) · Human Mutation · doi:10.1002/humu.23251 · Cited by 27
Stephens, R. M., Yi, M., Kessing, B. D., Nissley, D. V., & McCormick, F. P. (2017) · Cancer Informatics · doi:10.1177/1176935117711944 · Cited by 30
Sagar, A., Arif, E., Solanki, A. K., Srivastava, P. K., Janech, M. G., Kim, S. H., Lipschutz, J. H., Kwon, S., Ashish, & Nihalani, D. (2017) · Scientific Reports · doi:10.1038/s41598-017-12134-8 · Cited by 32
Translating current basic research into future therapies for neurofibromatosis type 1
Brosseau, J., Liao, C.-P., & Le, L. Q. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0903-x · Cited by 30
Raimondi, L., Raimondi, F. M., Pietranera, M., Rocco, A. D., Benedetto, L. D., Miele, E., Lazzeroni, R., Cimino, G. G., & Spinelli, G. P. (2021) · Cancers · doi:10.3390/cancers13081928 · Cited by 26
“KRAS is the most commonly mutated oncogene in human cancer, with mutations present in approximately 20% of all human cancers, and mutationally activated RASgenes have been thought to be the main cause of resistance in several cancers, impacting multiple cellular processes that are critical to tumor progression [27].”
BackgroundKRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies
Liguori, L., Salomone, F., Viggiano, A., Sabbatino, F., Pepe, S., Formisano, L., Bianco, R., & Servetto, A. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104554 · Cited by 31
Inhibition of Ral GTPases Using a Stapled Peptide Approach
Thomas, J. C., Cooper, J. M., Clayton, N. S., Wang, C., White, M. A., Abell, C., Owen, D., & Mott, H. R. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.720243 · Cited by 26
“Of these, the Raf, phosphoinositide 3-kinase (PI3K), and RalGEF are the best validated (6).”
BackgroundNärhi, K. M., Nagaraj, A. S., Parri, E., Turkki, R., van Duijn, P. W., Hemmes, A., Lahtela, J., Uotinen, V., Mäyränpää, M. I., Salmenkivi, K., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5059 · Cited by 23
“The MAPK, PI3K–AKT and LKB1–AMPK pathways all regulate mTORC1 signalling to control cell growth and survival [26,27], and loss of LKB1 activates FAK–SRC signalling to regulate invasiveness [14] (Figure 3A).”
BackgroundErber, J., Steiner, J. D., Isensee, J., Lobbes, L. A., Toschka, A., Beleggia, F., Schmitt, A., Kaiser, R. W. J., Siedek, F., Persigehl, T., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3959 · Cited by 33
Lin, Y.-H. T., Way, G. P., Barwick, B. G., Mariano, M. C., Marcoulis, M., Ferguson, I., Driessen, C., Boise, L., Greene, C. S., & Wiita, A. P. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000303 · Cited by 26
Liu, Z., Wang, M., Wang, H., Fang, L., & Gou, S. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112269 · Cited by 25
Small molecule inhibitors of RAS proteins with oncogenic mutations
Orgován, Z., & Keserű, G. M. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09911-9 · Cited by 28
Role of stromal activin A in human pancreatic cancer and metastasis in mice
Mancinelli, G. E., Torres, C., Krett, N. L., Bauer, J. I., Castellanos, K., McKinney, R., Dawson, D. W., Guzman, G., Hwang, R. F., Grimaldo, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-87213-y · Cited by 29
AGO2 promotes tumor progression in KRAS-driven mouse models of non–small cell lung cancer
Tien, J. C.-Y., Chugh, S., Goodrum, A. E., Cheng, Y., Mannan, R., Zhang, Y., Wang, L., Dommeti, V. L., Wang, X., Xu, A., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2026104118 · Cited by 28
“Biochemically, the active site binds GTP at picomolar affinity, hampering competitive inhibition (8, 9).”
Zeng, J., Weng, J., Zhang, Y., Xia, F., Cui, Q., & Xu, X. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c04679 · Cited by 24
Li, H., Qi, W.-L., Wang, Y., & Meng, L. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.08.011 · Cited by 32
“Despite its extreme importance in the development of tumors, direct inhibition of the mutated small GTPase has been challenging in the last few decades due to its high affinity with GTP and lack of a pocket for small molecules to bind with.(31) Therefore, mutated KRas has long been recognized as ‘undruggable’.”
BackgroundPan-RAS inhibitors: Hitting multiple RAS isozymes with one stone
Coley, A. B., Ward, A., Keeton, A. B., Chen, X., Maxuitenko, Y. Y., Prakash, A., Li, F., Foote, J. B., Buchsbaum, D. J., & Piazza, G. A. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.009 · Cited by 27
Caratti, B., Fidan, M., Caratti, G., Breitenecker, K., Engler, M., Kazemitash, N., Traut, R., Wittig, R., Casanova, E., Ahmadian, M. R., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abm4452 · Cited by 27
Buchou, C., Laud-Duval, K., van der Ent, W., Grossetête, S., Zaïdi, S., Gentric, G., Corbé, M., Müller, K., Nery, E. D., Surdez, D., et al. (2022) · Cancers · doi:10.3390/cancers14092327 · Cited by 27
“We demonstrated such an altered anchorage for RAC1, RHOA, and RAS, but the anchorage of many other membrane receptors, including GPCRs and growth factor receptors that play a role in the transduction of proliferation signals, is also expected to be impaired.”
BackgroundInfluentialMei, Y., Qin, X., Yang, Z., Song, S., Liu, X., Wu, C., Qian, J., Huang, X., Zhang, Y., & He, W. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.10.003 · Cited by 36
“…mutated oncogenes in gastrointestinal cancers [6,7], with downstream signaling pathways promoting cancer progression [8,9], and has long been considered "undruggable" [10,11] due to its nearly spherical structure, lack of a deep hydrophobic pocket, and absence of an obvious binding site [12].”
BackgroundYoum, I., West, M., Li, W., Du, X., Ewert, D. L., & Kopke, R. D. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.06.035 · Cited by 27
Martin, H. L., Bedford, R., Heseltine, S. J., Tang, A. A.-S., Haza, K. Z., Rao, A., McPherson, M. J., & Tomlinson, D. C. (2018) · New Biotechnology · doi:10.1016/j.nbt.2018.02.008 · Cited by 25
“Ras isoforms are mutated in approximately 30% of all human cancers, commonly causing decreased hydrolysis of GTP leading to constitutive activation [52], in theory making Ras an excellent candidate for anti-”
BackgroundInfluentialFirst SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia
Cho, H., Shin, I., Ju, E., Choi, S.-H., Hur, W., Kim, H., Hong, E., Kim, N. D., Choi, H. G., Gray, N. S., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00882 · Cited by 25
Wang, W., Park, C., Oh, E., Sung, Y., Lee, J., Park, K.-H., & Kang, H. (2019) · Journal of Natural Products · doi:10.1021/acs.jnatprod.9b00646 · Cited by 25
Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers
Mattox, T. E., Chen, X., Maxuitenko, Y. Y., Keeton, A. B., & Piazza, G. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010141 · Cited by 31
“HRAS mutations have less bias toward a specific codon with 50% occurring at codon 12, and 40% found at codon 61 [9].”
BackgroundYuan, T., Zeng, C., Liu, J., Zhao, C., Ge, F., Li, Y., Qian, M., Du, J., Wang, W., Li, Y., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01706-y · Cited by 26
Dynamic conformational equilibria in the active states of KRAS and NRAS
Rennella, E., Henry, C., Dickson, C. J., Georgescauld, F., Wales, T. E., Erdmann, D., Cotesta, S., Maira, S.-M., Sedrani, R. C., Brachmann, S. M., et al. (2024) · RSC Chemical Biology · doi:10.1039/d4cb00233d · Cited by 25
Wang, X., Li, S., Lin, S., Han, Y., Zhan, T., Huang, Z., Wang, J., Li, Y., Deng, H., Zhang, M., et al. (2025) · Cell Research · doi:10.1038/s41422-025-01085-9 · Cited by 31
“10,11 Activation of a kras mutation is a key driver of initiation and progression of many tumors and is essential for tumor growth.”
Shi, X., Li, S., Wang, L., Li, H., Li, Z., Wang, W., Bai, J., Sun, Y., Li, J., & Li, X. (2020) · Chinese Medicine · doi:10.1186/s13020-020-00340-y · Cited by 23
KRAS G12C fragment screening renders new binding pockets
Mathieu, M., Steier, V., Fassy, F., Delorme, C., Papin, D., Genêt, B., Duffieux, F., Bertrand, T., Delarbre, L., Le-Borgne, H., et al. (2021) · Small GTPases · doi:10.1080/21541248.2021.1979360 · Cited by 25
“Activating mutations of KRAS are some of the most frequently found in human cancers [3], and they are associated with poor prognosis, such as that seen, for example, in early-stage non-small cell lung cancer [4].”
BackgroundNakayama, A., Nagashima, T., Nishizono, Y., Kuramoto, K., Mori, K., Homboh, K., Yuri, M., & Shimazaki, M. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01629-x · Cited by 25
“The KRAS G12C mutation is found in ~13% of lung adenocarcinoma, 3% of colorectal cancer, 3% of pancreatic cancer and other solid tumours [4, 7].”
BackgroundPetruzzella, E., Braude, J. P., Aldrich-Wright, J. R., Gandin, V., & Gibson, D. (2017) · Angewandte Chemie · doi:10.1002/ange.201706739 · Cited by 24
KRAS as a Key Oncogene in the Clinical Precision Diagnosis and Treatment of Pancreatic Cancer
Dai, M., Chen, S., Teng, X., Chen, K., & Cheng, W. (2022) · Journal of Cancer · doi:10.7150/jca.76695 · Cited by 29
“KRAS mutations are the most common mutations in human solid tumors [6], and can be found in 90% of pancreatic cancer patients [7].”
BackgroundRAS‐targeted cancer therapy: Advances in drugging specific mutations
Liu, C., Ye, D., Yang, H., Chen, X., Su, Z., Li, X., Ding, M., & Liu, Y. (2023) · MedComm · doi:10.1002/mco2.285 · Cited by 30
Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy
Kirschner, T., Müller, M. P., & Rauh, D. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02403 · Cited by 24
Identification and affinity enhancement of T-cell receptor targeting a KRASG12V cancer neoantigen
Zhang, M., Xu, W. L., Luo, L., Guan, F., Wang, X., Zhu, P., Zhang, J., Zhou, X., Wang, F., & Ye, S. (2024) · Communications Biology · doi:10.1038/s42003-024-06209-2 · Cited by 25
Phylogenetic analysis of the SINA/SIAH ubiquitin E3 ligase family in Metazoa
Pepper, I., Sciver, R. E. V., & Tang, A. (2017) · BMC Evolutionary Biology · doi:10.1186/s12862-017-1024-x · Cited by 25
“However, the design of long-lasting anti-K-RAS therapies has remained elusive for past 40 years due to unique RAS kinetics, extensive pathway cross-talk, signal bifurcation, compensatory activation, feedback control, context-dependent adaptation and dynamic rewiring of the ERBB/K-RAS signaling network [11, 12].”
BackgroundRAS Regulates the Transition from Naive to Primed Pluripotent Stem Cells
Altshuler, A., Verbuk, M., Bhattacharya, S., Abramovich, I., Haklai, R., Hanna, J. H., Kloog, Y., Gottlieb, E., & Shalom‐Feuerstein, R. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.01.004 · Cited by 26
“The RAS inhibitor (RASi) farnesylthiosalicyclic acid disrupts RAS membrane anchorage and inhibits tumor cell growth (Bustinza-Linares et al., 2010; Cox et al., 2014; Shalom-Feuerstein et al., 2004; Weisz et al., 1999).”
BackgroundChemical Proteomic Characterization of a Covalent KRASG12C Inhibitor
Wijeratne, A., Xiao, J., Reutter, C., Furness, K. W., Leon, R., Zia-Ebrahimi, M., Cavitt, R. N., Strelow, J. M., Van Horn, R. D., Peng, S.-B., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00110 · Cited by 24
Functional Genomic Characterization of Cancer Genomes
Howard, T. P., Vázquez, F., Tsherniak, A., Hong, A. L., Rinne, M. L., Aguirre, A. J., Boehm, J. S., & Hahn, W. C. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.031070 · Cited by 27
“However, many of these mutations are currently thought to be “undruggable,” such as oncogenic KRAS and amplified MYC (Verdine and Walensky 2007; Cox et al. 2014).”
BackgroundMa, Z., Zhou, M., Shen, Q., & Zhou, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01441 · Cited by 31
Current and Emerging Treatment Paradigms in Colorectal Cancer: Integrating Hallmarks of Cancer
de Torres, C. S., Baraibar, I., Gonzalez, N. S., Ros, J., Salvà, F., Rodríguez-Castells, M., Alcaráz, A., García, A., Tabernero, J. M., & Élez, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136967 · Cited by 29
“…and panitumumab) have improved outcomes in patients with RAS wild-type advanced CRC [9,10], whereas activating mutations in KRAS or NRAS , present in 52% of metastatic CRC [11], provide resistance to anti-EGFR therapies, as the downstream activation of the signaling pathway is independent of EGFR.”
BackgroundAdvances in the Genetics and Biology of Pancreatic Cancer
Aguirre, A. J., & Collisson, E. A. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000286 · Cited by 25
Small-Molecule Screening for Genetic Diseases
Markossian, S., Ang, K. K. H., Wilson, C. G. M., & Arkin, M. R. (2018) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083117-021452 · Cited by 26
Liu, K., Guo, J., Liu, K., Fan, P., Zeng, Y., Xu, C., Zhong, J., Li, Q., & Zhou, Y. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.09.034 · Cited by 23
“KRASmutations occur in ~30% of lung adenocarcinomas [1,2].”
BackgroundTargeting RAS in pediatric cancer: is it becoming a reality?
Vaseva, A. V., & Yohe, M. E. (2019) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000856 · Cited by 27
“As direct targeting of mutant RAS with small molecules proved to be difficult, initial strategies for targeting RAS were focused on inhibition of downstream signaling pathways [3].”
BackgroundInfluentialBlocking STAT3 by pyrvinium pamoate causes metabolic lethality in KRAS-mutant lung cancer
Feng, J., Jiang, W., Liu, Y., Huang, W., Hu, K., Li, K., Chen, J., Ma, C., Sun, Z., & Pang, X. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113960 · Cited by 23
Inhibitory activity of acteoside in melanoma via regulation of the ERβ-Ras/Raf1-STAT3 pathway
Wu, Y., Zeng, M., Xu, R., Zhang, B., Wang, S., Li, B., Kan, Y., Cao, B., Zheng, X., & Feng, W. (2021) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2021.108978 · Cited by 25
Nussinov, R., Tsai, C., & Jang, H. (2021) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2021.05.009 · Cited by 24
Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS‐mutant cancer
Zhang, Y., Liang, S., Saliakoura, M., Yang, H., Vassella, E., Konstantinidou, G., Tschan, M. P., Hegedűs, B., Zhao, L., Gao, Y., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013193 · Cited by 25
“Unlike NSCLC driven by other less frequent oncogenic drivers (e.g., EGFR , ALK , MET1 , and ROS1 ) that significantly benefit from selective kinase inhibitors (Reck & Rabe, 2017), there are still no clinically approved therapies that specifically target KRAS -mutant cancers (Cox et al , 2014).”
Garcia, N., Pozo, V. D., Yohe, M. E., Goodwin, C. M., Shackleford, T. J., Wang, L., Baxi, K., Chen, Y., Rogojina, A. T., Zimmerman, S. M., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0194 · Cited by 28
“The two key RAS effector pathways PI3K-AKT-mTOR and RAFMEK-ERK are the most attractive targets for RAS-driven cancers and have received the highest interest in both academia and industry (10).”
BackgroundTargeting RAS in neuroblastoma: Is it possible?
Lin, L., Miao, L., Lin, H., Cheng, J., Li, M., Zhuo, Z., & He, J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108054 · Cited by 24
Exosomes in the Treatment of Pancreatic Cancer: A Moonshot to PDAC Treatment?
Papadakos, S. P., Dedes, N., Pergaris, A., Gazouli, M., & Theocharis, S. E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073620 · Cited by 24
Islam, M. M., Goertzen, A., Singh, P. K., & Saha, R. (2022) · iScience · doi:10.1016/j.isci.2022.104483 · Cited by 25
Chee, C. W., Zamakshshari, N. H., Lee, V. S., Abdullah, I., Othman, R., Lee, Y. K., Hashim, N. M., & Rashid, N. N. (2022) · PLoS ONE · doi:10.1371/journal.pone.0270970 · Cited by 30
“KRAS are the most frequently mutated oncogenes in human cancer among the three human Ras genes (KRAS, NRAS and HRAS) appearing in 45% of CRC which makes Ras one of the most crucial targets in oncology for drug development [41].”
Background
Metadata
- Authors
- Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Vanderbilt University (US)
- Dana-Farber Cancer Institute (US)
- National Cancer Institute (US)
- Corresponding author
- Der, Channing J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-10-17
- Volume
- 13
- Issue
- 11
- Pages
- 828-851
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC4355017
- OpenAlex
- W2081990599
- Cited by
- 1,997
- References
- 231
- Citations by year
- 2026: 134 · 2025: 160 · 2024: 194 · 2023: 185 · 2022: 213 · 2021: 237 · 2020: 204 · 2019: 166 · 2018: 156 · 2017: 166 · 2016: 106 · 2015: 71 · 2014: 2
- FWCI
- 10.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (DP1OD006933, 5r01ca042978-30)
- U.S. Public Health Service (P50A095103-12)
- National Cancer Institute (P50CA127003, CA042978, R01CA175747, DP1CA174419, P50CA095103, CA175747, R01-CA042978, R21CA179193, RC2CA148375, CA179193, R01CA157490)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- oncogenic Ras, RAS inhibitors, undruggable targets, synthetic lethality, RAS-mutant cancers, anticancer drug discovery, Ras signaling
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Signal Transduction, Oncogene Proteins, ras Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.